(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats
| Autor: | Abraham Fisher, Aharon Levy, Rachel Brandeis, Shlomit Dachir, Eliahu Heldman, Ishai Karton, M. Sapir, Z. Pittel |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Agonist
Male Quinuclidines medicine.drug_class Radial maze Aziridines Thiophenes Pharmacology Muscarinic agonist Choline chemistry.chemical_compound Alzheimer Disease Muscarinic acetylcholine receptor medicine Animals Low toxicity Behavior Animal Molecular Structure General Neuroscience Cognition Rats Inbred Strains Receptors Muscarinic Rats Disease Models Animal chemistry Parasympathomimetics Drug Design Cholinergic Cognition Disorders Neuroscience Quinuclidine |
| Zdroj: | Neuroscience letters. 102(2-3) |
| ISSN: | 0304-3940 |
| Popis: | (±)- cis -2-Methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine (AF102B), a new muscarinic agonist of utmost rigidity, exhibits a high selectivity for M 1 muscarinic receptors. In rats having a cholinergic hypofunction induced by the intracerebroventricular administration of ethylcholine aziridinium (AF64A), AF102B reversed cognitive impairments in a step-through passive avoidance task and in an 8-arm radial maze. AF102B reversed cognitive impairments at significantly lower doses than those needed to induce side-effects. In addition, AF102B exhibited low toxicity. The results suggest that AF102B may prove useful for treatments of cholinergic deficiencies and cognitive impairments, like those reported in Alzheimer's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|